[go: up one dir, main page]

WO2004039359A3 - Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders - Google Patents

Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders Download PDF

Info

Publication number
WO2004039359A3
WO2004039359A3 PCT/US2003/013784 US0313784W WO2004039359A3 WO 2004039359 A3 WO2004039359 A3 WO 2004039359A3 US 0313784 W US0313784 W US 0313784W WO 2004039359 A3 WO2004039359 A3 WO 2004039359A3
Authority
WO
WIPO (PCT)
Prior art keywords
proliferative disorders
hyper
manifacture
medicament
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/013784
Other languages
French (fr)
Other versions
WO2004039359A2 (en
Inventor
Jill E Wood
Yuanwei Chen
Barry Hart
Lin Yi
Jianqing Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Priority to AU2003301758A priority Critical patent/AU2003301758A1/en
Publication of WO2004039359A2 publication Critical patent/WO2004039359A2/en
Publication of WO2004039359A3 publication Critical patent/WO2004039359A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of treating hyper-proliferative disorders comprising the administration to a patient in need thereof of an effective amount of a compound of Formula (I) wherein R is halo or CF3; n is 0 or 1; R1 is selected independently in each instance from the group consisting of halo, (C1-C3)alkoxy, and (C1-C3)alkylthiol; m is 1 or 2; or pharmaceutically acceptable salt thereof.
PCT/US2003/013784 2002-05-06 2003-05-02 Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders Ceased WO2004039359A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003301758A AU2003301758A1 (en) 2002-05-06 2003-05-02 Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37833002P 2002-05-06 2002-05-06
US60/378,330 2002-05-06

Publications (2)

Publication Number Publication Date
WO2004039359A2 WO2004039359A2 (en) 2004-05-13
WO2004039359A3 true WO2004039359A3 (en) 2004-07-22

Family

ID=32230080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/013784 Ceased WO2004039359A2 (en) 2002-05-06 2003-05-02 Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders

Country Status (2)

Country Link
AU (1) AU2003301758A1 (en)
WO (1) WO2004039359A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7557210B2 (en) 2002-02-01 2009-07-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7989448B2 (en) 2005-01-19 2011-08-02 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004265288A1 (en) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064655A1 (en) * 2000-03-01 2001-09-07 Astrazeneca Ab 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064655A1 (en) * 2000-03-01 2001-09-07 Astrazeneca Ab 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ABOU OUF A A ET AL: "Preparation of some methyl pyrimidines. Expected to be Antimetabilites", 1973, EGYPTIAN JOURNAL OF PHARMACEUTICAL SCIENCES, NATIONAL INFORMATION AND DOCUMENTATION CENTRE,, EG, PAGE(S) 180-195, ISSN: 0301-5068, XP009028502 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7557210B2 (en) 2002-02-01 2009-07-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9913842B2 (en) 2002-02-01 2018-03-13 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9416112B2 (en) 2002-02-01 2016-08-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9346765B2 (en) 2002-02-01 2016-05-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9018204B1 (en) 2002-02-01 2015-04-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8557806B2 (en) 2002-07-29 2013-10-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US8785437B2 (en) 2005-01-19 2014-07-22 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8476263B2 (en) 2005-01-19 2013-07-02 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9266912B2 (en) 2005-01-19 2016-02-23 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8211889B2 (en) 2005-01-19 2012-07-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8211888B2 (en) 2005-01-19 2012-07-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9532998B2 (en) 2005-01-19 2017-01-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7989448B2 (en) 2005-01-19 2011-08-02 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses

Also Published As

Publication number Publication date
AU2003301758A8 (en) 2004-05-25
WO2004039359A2 (en) 2004-05-13
AU2003301758A1 (en) 2004-05-25

Similar Documents

Publication Publication Date Title
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
WO2005056524A3 (en) Therapeutic agents useful for treating pain
MXPA04001889A (en) Alkyne-aryl phosphodiesterase-4 inhibitors.
IN2015DN01132A (en)
NZ545506A (en) Therapeutic agents useful for treating pain
WO2004060882A8 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
WO2004072031A3 (en) Phenylacetamides and their use as glucokinase modulators
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
WO2005047244A3 (en) Inhibition of fgfr3 and treatment of multiple myeloma
NZ544009A (en) Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
WO2002076472A3 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
NO20052883L (en) New drugs for the treatment of chronic obstructive airway disease.
WO2004037789A8 (en) Methylene urea derivatives as raf-kinase inhibitors
UA85708C2 (en) Benzoxazine-containing pharmaceutical combinations for treating respiratory tract diseases
WO2004029031A3 (en) Therapeutic piperazine compounds
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
PE20030061A1 (en) 1-BIARIL-1,8-NAPHTHYRIDIN-4-ONA AS PHOSPHODIESTERASE-4 INHIBITORS
WO1999049854A3 (en) Use of dexmedetomidine for icu sedation
IL162515A (en) Substituted diketopiperazines as oxytocin antagonists
WO2005016327A3 (en) Treatment of sleep disorders with cholinesterase inhibitors
CA2427814A1 (en) A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
WO2003051276A3 (en) Therapeutic heterocycles
WO2004039359A3 (en) Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders
WO2004052350A3 (en) Method of treating movement disorders using barbituric acid derivatives
WO2001016096A3 (en) Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP